ArticleMolecular biology reports2026
DHRS2 regulates epithelial-mesenchymal transition in breast cancer cells.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveBreast cancer is the most common malignancy among women, and metastatic cases have a significantly poorer prognosis than non-metastatic disease. Epithelial-mesenchymal transition (EMT), characterized by the acquisition of mesenchymal features and enhanced migratory capacity by epithelial cells, is a key mechanism underlying cancer metastasis. DHRS2 has recently gained attention for its role in proliferation, invasion, and apoptosis in breast cancer. This study aimed to investigate the relationship between DHRS2 and EMT-related genes in breast cancer. METHODS AND
resultsDHRS2 was overexpressed in MCF7 breast cancer cells using a liposomal transfection agent, while a knockout model was generated using a lentivirus-mediated CRISPR-Cas9 system. Overexpression was confirmed by RT-PCR, whereas knockout was validated by Sanger sequencing and Western blot analysis. Following genetic modifications, EMT-related gene expression levels were analysed by RT-PCR and compared with wild-type MCF7 cells. Altered DHRS2 expression significantly affected the expression of WNT3A, WNT4, TMED9, and SDC1. These findings suggest that DHRS2 regulates EMT through the Wnt/β-catenin signalling pathway. In addition, the limited changes observed in certain EMT markers indicate that DHRS2 may promote cell migration through partial EMT rather than complete EMT.
conclusionDHRS2 may influence cellular fate and metastatic potential by regulating EMT processes through multiple signalling pathways, particularly Wnt/β-catenin signalling.
Indexed as
Identifiers
42573658What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.